A daily review of books worth your time

As an Amazon Associate we earn from qualifying purchases. Prices may vary.
John Carreyrou's Bad Blood reconstructs the rise and collapse of Theranos, the blood-testing startup that promised a medical revolution and delivered fraud. It's investigative journalism written with the propulsion of a thriller, and a clear-eyed study of how charisma, money, and fear can keep a lie standing far longer than it should.
The Review
What makes this book work isn't the scandal itself, eye-popping as it is, but the discipline of the reporting underneath it. Carreyrou, the Wall Street Journal reporter who broke the story, builds the Theranos saga the way you'd build a legal case: source by source, deposition by deposition, scene by scene. He resists the temptation to psychoanalyze Elizabeth Holmes from a distance. Instead he shows you the actual machinery of deception — the prototype that smeared blood and produced unreliable results, the demos rigged to hide failures, the way executives shuffled samples to commercial analyzers while telling the world their device did it all from a single fingerstick.
The structure is one of the book's quiet strengths. Carreyrou follows employees in roughly chronological order, letting us meet smart, idealistic people who join the company, sense something is wrong, raise it, and get crushed or pushed out. Because he keeps cycling through these individual stories, the pattern becomes undeniable. You watch the same betrayal happen again and again, and the cumulative effect is far more damning than any single accusation. The tension in the back half — when Carreyrou himself enters the narrative as the reporter Theranos's lawyers tried to intimidate into silence — reads like a legal thriller, except every threatening letter and surveillance detail is documented.
The human cost is where the book lands hardest. This wasn't a story about vaporware that wasted venture money. Faulty tests went to real patients who got false cancer scares, dangerous miscalibrations, results that could have steered actual medical decisions. Carreyrou never sensationalizes this, but he never lets you forget it either. The recklessness at the center of Theranos becomes morally serious in a way a lot of Silicon Valley failure stories aren't.
What you come away understanding is bigger than one company. Carreyrou anatomizes how the fake-it-till-you-make-it ethos of startup culture curdles when applied to medicine, how a board stacked with famous names and zero scientific expertise provided cover instead of oversight, and how a culture of secrecy, NDAs, and legal intimidation can suppress dissent for years. The portrait of Holmes is careful and restrained — he shows her drive and her lies without pretending to fully explain her — and that restraint makes the book more credible, not less.
The prose is clean and functional rather than lyrical; Carreyrou is a reporter, not a stylist, and the book moves on the strength of its facts and pacing. The new afterword covering the trial and sentencing gives the story a real ending, which earlier editions lacked. For anyone interested in how fraud actually operates from the inside, how journalism holds power accountable, or simply how an entire ecosystem of investors and prestige can be conned, this is about as instructive and absorbing as nonfiction gets.
Reviewed by Ellis
As an Amazon Associate we earn from qualifying purchases. Prices may vary.